Idiopathic Pulmonary Fibrosis (IPF): An Overview Shaney L. Barratt 1,2,*, Andrew Creamer 1, Conal Hayton 3 and Nazia Chaudhuri 3 1 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK;andrew.creamer@nbt.nhs.uk2 Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK3 North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, […]
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | |
#BreathingLife #CurePF #PFMonth #pulmonaryfibrosis #UseYourLungs ACEi Action for Pulmonary Fibrosis Angiotensin-converting enzyme inhibitor Angiotensin II receptor blocker Angiotensin modulators Angiotensin peptides Antifibrotic therapies CD1d molecules chronic inflammation Exercise Exercise-based pulmonary rehabilitation fibroblasts fibrosis Forced vital capacity FVC Idiopathic pulmonary fibrosis Interstitial lung disease IPF Macrophages Natural killer T cells NKT Pathogenesis Pleuroparenchymal fibroelastosis Post hoc analysis PPFE Pulmonary Fibrosis Pulmonary Fibrosis Research and Education Hub Pulmonary rehabilitation Slower disease progression tissue fibrosis Upper lobe fibroelastosis